IP Library Granted Patent US 7,981,907
Granted Patent B2
US 7,981,907 · App. 12/199,167 · Granted Jul 19, 2011

Thio-substituted biarylmethanesulfinyl derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,981,907
App. No.
12/199,167
Granted
Jul 19, 2011
Kind
B2
Abstract

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R 1 , R 2 , R 4 , R 5 , q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.

Claims (2138)

1. A method of treating sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of Formula (I):

or a stereoisomeric form, mixture of stereoisomeric forms or pharmaceutically acceptable salt form thereof,

wherein:

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or

5 to 14 membered heteroaryl group substituted by 0-5 R 3 , wherein said heteroaryl group is selected from phenoxathiinyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, imidazopyridinyl, triazolyl, purine and 2-benzo[1,4]dioxine;

Y is C 1 -C 6 alkylene substituted with 0-3 R 20A ;

R 1 is selected from H, C(═O)NR 12 R 13 , C(═N)NR 12 R 13 , OC(═O)NR 12 R 13 , NR 21 C(═O)NR 12 R 13 , NR 21 S(═O) 2 NR 12 R 13 , —(C 6 -C 10 aryl)-NR 12 R 13 wherein said aryl is substituted with 0-3 R 20 ; NR 21 C(═O)R 14 , C(═O)R 14 , C(═O)OR 11 , OC(═O)R 11 , and NR 21 S(═O) 2 R 11 ;

R 2 is selected from H, F, Cl, Br, I, OR 16 , OR 25 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NR 15 C(═O)R 16 , NR 15 CO 2 R 16 , OC(═O)NR 17 R 18 , NR 15 C(═S)R 16 , SR 16 , S(═O)R 16 , and S(═O) 2 R 16 ;

alternatively, two R 2 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 3 is selected from H, F, Cl, Br, I, OR 16 , OCF 3 , OR 25 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , CH 2 OR 16 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl, C 7 -C 10 arylalkyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NR 15 C(═O)R 16 , NR 15 CO 2 R 16 , OC(═O)NR 17 R 18 , NR 15 C(═S)R 16 , SR 16 , S(═O)R 16 , S(═O) 2 R 16 , and NR 15 S(═O) 2 R 16 ;

alternatively, two R 3 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 4 and R 5 at each occurrence are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

alternatively, R 4 and R 5 , together with the carbon atom to which they are attached, form a 3-7 membered spirocyclic ring;

R 11 at each occurrence is independently selected from H, C 1 -C 6 alkyl substituted with 0-3 R 20 ; and C 6 -C 10 aryl substituted with 0-3 R 20 ;

R 12 and R 13 at each occurrence are each independently selected from H, C 1 -C 6 alkyl substituted with 0-3 R 20 ; and C 6 -C 10 aryl substituted with 0-3 R 20 ;

alternatively, R 12 and R 13 , together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring substituted with 0-3 R 20 , wherein said heterocyclic ring is selected from piperazinyl, piperidinyl and pyrrolidinyl;

R 14 at each occurrence is independently selected from C 1 -C 6 alkyl substituted with 0-3 R 20 ; C 6 -C 10 aryl substituted with 0-3 R 20 ; and C 7 -C 10 arylalkyl substituted with 0-3 R 20 ;

R 15 at each occurrence is independently selected from H and C 1 -C 6 alkyl;

R 16 at each occurrence is independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl;

R 17 and R 18 at each occurrence are each independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl,

R 20 at each occurrence is independently selected from F, Cl, Br, I, OH, OR 22 , OR 25 , NR 23 R 24 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl substituted by 0-1 R 26 ; C 7 -C 10 arylalkyl, ═O, C(═O)R 22 , C(═O)OR 22 , OC(═O)R 22 , C(═O)NR 23 R 24 , NR 21 C(═O)R 22 , NR 21 CO 2 R 22 , OC(═O)NR 23 R 24 , NR 21 C(═S)R 22 , SR 22 , S(═O)R 22 , and S(═O) 2 R 22 ;

R 20A at each occurrence is independently selected from F, Cl, OH, C 1 -C 6 alkoxy, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 3 -C 7 cycloalkyl;

R 21 at each occurrence is independently selected from H and C 1 -C 6 alkyl;

R 22 at each occurrence is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, and C 6 -C 10 aryl;

R 23 and R 24 at each occurrence are each independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl,

R 25 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;

R 26 at each occurrence is independently selected from H, F, Cl, Br, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;

x is 0, 1, 2, 3, or 4; and

q is 1, or 2;

provided

when Y is —CH 2 —, Ar is phenyl substituted by 0-5 R 3 , and —C(R 4 )(R 5 )— is —CH(C 1 -C 3 alkyl)-, then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Y is —CH 2 —, R 1 is H, C(═O)OR 11 , or C(═O)NR 12 R 13 ; Ar is phenyl substituted by 0-2 R 3 , and R 3 is H, F, Cl, Br, I, CH 3 , OCH 3 , SCH 3 , CN, NO 2 , or methylenedioxyphenyl; then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Ar is imidazopyridine substituted by 0-5 R 3 , Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Ar is in the meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring and Ar is a heteroaryl group attached to the phenyl ring through a nitrogen atom, then Ar is pyrrolyl, indolyl, triazolyl, or 1,3-dihydroisoindolyl;

when Y is —CH 2 — and Ar is pyridyl substituted by a nitro, a methyl, a second methyl, and a C(═O)OC 3 H 7 group, then R 1 is not H;

when Y is —CH 2 — and Ar is a purine or imidazopyridine substituted by 0-5 R 3 , then R 1 is not H;

when q is 1, Y is butylene and Ar is phenyl, substituted by 0-5 R 3 , in the para position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H;

when q is 1, Y is —CH 2 — or —CH 2 CH 2 —, and Ar is pyrrolyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring; then R 1 is not H;

when q is 1, R 2 is OH, and Ar is phenyl or cycloalkenyl; then R 1 is not H or C(═O)OR 11 ;

when q is 1, Y is —CH 2 —, R 4 is H, R 5 is H, and Ar is phenyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H;

when q is 2, then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when q is 2, Y is —CH 2 —, R 4 is H, R 5 is H, and Ar is 1,2-(methylenedioxy)-phenyl, then Ar is in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring; and

when q is 2, and Ar is phenyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H.

2. The method of claim 1 , wherein the compound is administered for the treatment of sleepiness associated with narcolepsy.

3. A method for the promotion of wakefulness comprising administering a compound of Formula (I):

or a stereoisomeric form, mixture of stereoisomeric forms or pharmaceutically acceptable salt form thereof,

wherein:

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or

5 to 14 membered heteroaryl group substituted by 0-5 R 3 , wherein said heteroaryl group is selected from phenoxathiinyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, imidazopyridinyl, triazolyl, purine and 2-benzo[1,4]dioxine;

Y is C 1 -C 6 alkylene substituted with 0-3 R 20A ;

R 1 is selected from H, C(═O)NR 12 R 13 , C(═N)NR 12 R 13 , OC(═O)NR 12 R 13 , NR 21 C(═O)NR 12 R 13 , NR 21 S(═O) 2 NR 12 R 13 , —(C 6 -C 10 aryl)-NR 12 R 13 wherein said aryl is substituted with 0-3 R 20 ; NR 21 C(═O)R 14 , C(═O)R 14 , C(═O)OR 11 , OC(═O)R 11 , and NR 21 S(═O) 2 R 11 ;

R 2 is selected from H, F, Cl, Br, I, OR 16 , OR 25 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NR 15 C(═O)R 16 , NR 15 CO 2 R 16 , OC(═O)NR 17 R 18 , NR 15 C(═S)R 16 , SR 16 , S(═O)R 16 , and S(═O) 2 R 16 ;

alternatively, two R 2 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 3 is selected from H, F, Cl, Br, I, OR 16 , OCF 3 , OR 25 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , CH 2 OR 16 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl, C 7 -C 10 arylalkyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NR 15 C(═O)R 16 , NR 15 CO 2 R 16 , OC(═O)NR 17 R 18 , NR 15 C(═S)R 16 , SR 16 , S(═O)R 16 , S(═O) 2 R 16 , and NR 15 S(═O) 2 R 16 ;

alternatively, two R 3 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 4 and R 5 at each occurrence are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

alternatively, R 4 and R 5 , together with the carbon atom to which they are attached, form a 3-7 membered spirocyclic ring;

R 11 at each occurrence is independently selected from H, C 1 -C 6 alkyl substituted with 0-3 R 20 ; and C 6 -C 10 aryl substituted with 0-3 R 20 ;

R 12 and R 13 at each occurrence are each independently selected from H, C 1 -C 6 alkyl substituted with 0-3 R 20 ; and C 6 -C 10 aryl substituted with 0-3 R 20 ;

alternatively, R 12 and R 13 , together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring substituted with 0-3 R 20 , wherein said heterocyclic ring is selected from piperazinyl, piperidinyl and pyrrolidinyl;

R 14 at each occurrence is independently selected from C 1 -C 6 alkyl substituted with 0-3 R 20 ; C 6 -C 10 aryl substituted with 0-3 R 20 ; and C 7 -C 10 arylalkyl substituted with 0-3 R 20 ;

R 15 at each occurrence is independently selected from H and C 1 -C 6 alkyl;

R 16 at each occurrence is independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl;

R 17 and R 18 at each occurrence are each independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl,

R 20 at each occurrence is independently selected from F, Cl, Br, I, OH, OR 22 , OR 25 , NR 23 R 24 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl substituted by 0-1 R 26 ; C 7 -C 10 arylalkyl, ═O, C(═O)R 22 , C(═O)OR 22 , OC(═O)R 22 , C(═O)NR 23 R 24 , NR 21 C(═O)R 22 , NR 21 CO 2 R 22 , OC(═O)NR 23 R 24 , NR 21 C(═S)R 22 , SR 22 , S(═O)R 22 , and S(═O) 2 R 22 ;

R 20A at each occurrence is independently selected from F, Cl, OH, C 1 -C 6 alkoxy, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, and C 3 -C 7 cycloalkyl;

R 21 at each occurrence is independently selected from H and C 1 -C 6 alkyl;

R 22 at each occurrence is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, and C 6 -C 10 aryl;

R 23 and R 24 at each occurrence are each independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl;

R 25 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;

R 26 at each occurrence is independently selected from H, F, Cl, Br, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;

x is 0, 1, 2, 3, or 4; and

q is 1, or 2;

provided

when Y is —CH 2 —, Ar is phenyl substituted by 0-5 R 3 , and —C(R 4 )(R 5 )— is —CH(C 1 -C 3 alkyl)-, then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Y is —CH 2 —, R 1 is H, C(═O)OR 11 , or C(═O)NR 12 R 13 ; Ar is phenyl substituted by 0-2 R 3 , and R 3 is H, F, Cl, Br, I, CH 3 , OCH 3 , SCH 3 , CN, NO 2 , or methylenedioxyphenyl;

then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Ar is imidazopyridine substituted by 0-5 R 3 , Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Ar is in the meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring and Ar is a heteroaryl group attached to the phenyl ring through a nitrogen atom, then Ar is pyrrolyl, indolyl, triazolyl, or 1,3-dihydroisoindolyl;

when Y is —CH 2 — and Ar is pyridyl substituted by a nitro, a methyl, a second methyl, and a C(═O)OC 3 H 7 group, then R 1 is not H;

when Y is —CH 2 — and Ar is a purine or imidazopyridine substituted by 0-5 R 3 , then R 1 is not H;

when q is 1, Y is butylene and Ar is phenyl, substituted by 0-5 R 3 , in the para position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H;

when q is 1, Y is —CH 2 — or —CH 2 CH 2 —, and Ar is pyrrolyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring; then R 1 is not H;

when q is 1, R 2 is OH, and Ar is phenyl or cycloalkenyl; then R 1 is not H or C(═O)OR 11 ;

when q is 1, Y is —CH 2 —, R 4 is H, R 5 is H, and Ar is phenyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H;

when q is 2, then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when q is 2, Y is —CH 2 —, R 4 is H, R 5 is H, and Ar is 1,2-(methylenedioxy)-phenyl,

then Ar is in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring; and

when q is 2, and Ar is phenyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H.

4. The method of claim 1 or 3 wherein the compound of Formula I has the following structure:

and is selected from the following:

Ar

Ex. No.

Ar

Position

q

Y-R 1

1

3-thienyl

ortho

1

CH 2 CONH 2

2

3-thienyl

ortho

1

CH 2 CO-N-pyrrolidinyl

3

3-thienyl

ortho

1

CH 2 CON(CH 3 ) 2

4

3-thienyl

ortho

1

CH 2 CONHCH(CH 3 ) 2

5

3-thienyl

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

6

3-thienyl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

7

3-thienyl

ortho

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

9

3-thienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxamide)-

piperazinyl

10

3-thienyl

ortho

1

CH 2 CO-1-(4-carboxamide)-

piperazinyl

11

3-thienyl

ortho

1

CH 2 CO-1-(4-phenylcarboxamide)-

piperazinyl

12

3 -thienyl

ortho

1

CH 2 CO-N-piperazinyl

13

3-thienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxylate)-

piperazinyl

14

3 -thienyl

ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

15

3-thienyl

ortho

1

CH 2 COOH

16

3-thienyl

ortho

2

CH 2 CO-1-(4-acetyl)-piperazinyl

17

5-chloro-

ortho

1

CH 2 CONH 2

2-thienyl

18

4-methyl-

ortho

1

CH 2 CONH 2

3-thienyl

19

3-thienyl

meta

1

CH 2 CONH 2

20

3-thienyl

meta

1

CH 2 CO-N-pyrrolidinyl

21

3-thienyl

meta

1

CH 2 CON(CH 3 ) 2

22

3-thienyl

meta

1

CH 2 CONHCH(CH 3 ) 2

23

3-thienyl

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

24

3-thienyl

meta

1

CH 2 CONH(CH 2 ) 2 OH

25

3-thienyl

meta

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

26

3-thienyl

meta

1

CH 2 CO-1-(4-phenyl)-piperazinyl

27

3-thienyl

meta

1

CH 2 CO-1-(4-ethylcarboxylate)-

piperazinyl

28

3-thienyl

meta

1

CH 2 CO-1-(4-methyl)-piperazinyl

29

3-thienyl

meta

1

CH 2 CO-N-piperazinyl

30

3-thienyl

meta

1

CH 2 CO-1-(4-carboxamide)-

piperazinyl

31

3-thienyl

meta

1

CH 2 CO-1-(4-propylphenyl)-

piperazinyl

32

3-thienyl

meta

1

CH 2 CO-1-(4-propyl)-piperazinyl

33

5-chloro-

meta

1

CH 2 CONH 2

2-thienyl

34

3-thienyl

para

1

CH 2 CO-N-pyrrolidinyl

35

3-thienyl

para

1

CH 2 CONH 2

36

3-thienyl

para

1

CH 2 CON(CH 3 ) 2

37

3-thienyl

para

1

CH 2 CONHCH(CH 3 ) 2

38

3-thienyl

para

1

CH 2 CONHCH 2 CN

39

3-thienyl

para

1

CH 2 CO-1-(4-acetyl)-piperazinyl

40

3-thienyl

para

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

41

3-thienyl

para

1

CH 2 CO-1-(4-methyl)-piperazinyl

42

3-thienyl

para

1

CH 2 CO-1-(4-cyclohexyl)-piperazinyl

43

3 -thienyl

para

1

CH 2 CO-1-(4-ethylcarboxylate)-

piperazinyl

44

3-thienyl

para

1

CH 2 CO-1-(4-carboxamide)-

piperazinyl

45

3-thienyl

para

1

CH 2 CO-N-piperazinyl

46

3-thienyl

para

1

CH 2 CO-1-(4-ethylcarboxamide)-

piperazinyl

47

2-benzo-

ortho

1

CH 2 CONH 2

thienyl

48

2-benzo-

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

thienyl

49

2-benzo-

ortho

1

CH 2 CO-1-(4-ethylcarboxylate)-

thienyl

piperazinyl

50

2-benzo-

ortho

1

CH 2 CO-N-piperazinyl

thienyl

51

2-benzo-

ortho

1

CH 2 CO-1-(4-carboxamide)-

thienyl

piperazinyl

52

2-benzo-

ortho

1

CH 2 CO-1-(4-ethylcarboxamide)-

thienyl

piperazinyl

53

2-benzo-

ortho

1

CH 2 CO-1-(4-phenylcarboxamide)-

thienyl

piperazinyl

55

2-benzo-

ortho

1

(CH 2 ) 2 CONH 2

thienyl

56

2-benzo-

ortho

1

(CH 2 ) 2 CO-1-(4-methyl)-piperazinyl

thienyl

57

2-benzo-

ortho

1

CH 2 COOH

thienyl

58

2-benzo-

ortho

2

CH 2 CONH 2

thienyl

59

2-(1,1-

ortho

2

CH 2 CONH 2

dioxo)-

benzo-

thienyl

60

2-benzo-

ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

thienyl

61

3-benzo-

ortho

1

CH 2 CONH 2

thienyl

63

3-benzo-

ortho

1

(CH 2 ) 2 CO-1-(4-methyl)-piperazinyl

thienyl

64

3-benzo-

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

thienyl

65

3-benzo-

ortho

1

CH 2 CO-1-(4-ethylcarboxylate)-

thienyl

piperazinyl

66

3 -benzo-

ortho

1

CH 2 CO-1-(4-hydroxyethyl)-

thienyl

piperazinyl

67

2-benzo-

meta

1

CH 2 CONH 2

thienyl

68

2-benzo-

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

thienyl

69

2-benzo-

meta

1

CH 2 CO-1-(4-methyl)-piperazinyl

thienyl

70

2-benzo-

meta

1

CH 2 CONHCH(CH 3 ) 2

thienyl

72

2-benzo-

meta

1

CH 2 CO-1-(4-ethylcarboxylate)-

thienyl

piperazinyl

73

2-benzo-

meta

1

CH 2 CON(C 2 H 5 ) 2

thienyl

74

2-benzo-

para

1

CH 2 CONH 2

thienyl

75

2-benzo-

para

1

CH 2 CO-1-(4-acetyl)-piperazinyl

thienyl

76

2-benzo-

meta

1

CH 2 CO-1-(4-hydroxyethyl)-

thienyl

piperazinyl

77

3 -benzo-

meta

1

CH 2 CONH 2

thienyl

78

3 -benzo-

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

thienyl

79

3 -benzo-

meta

1

CH 2 CO-1-(4-methyl)-piperazinyl

thienyl

80

3 -benzo-

meta

1

CH 2 CO-1-(4-hydroxyethyl)-

thienyl

piperazinyl

81

3 -benzo-

meta

1

CH 2 CO-1-(4-ethylcarboxylate)-

thienyl

piperazinyl

82

2-benzo-

para

1

CH 2 CO-1-(4-methyl)-piperazinyl

thienyl

83

2-benzo-

para

1

CH 2 CO-1-(4-hydroxyethyl)-

thienyl

piperazinyl

84

3 -benzo-

para

1

CH 2 CONH 2

thienyl

85

2-indolyl

ortho

1

CH 2 CONH 2

86

3-furyl

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

87

3-furyl

ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

88

3-furyl

ortho

1

CH 2 CONH 2

89

3-pyridyl

ortho

1

CH 2 CONH(isopropyl)

90

3-pyridyl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

91

3-pyridyl

ortho

1

CH 2 CONH 2

92

3-pyridyl

ortho

1

CH 2 CONH 2

93

3-pyridyl

meta

1

CH 2 CONH 2

94

3-pyridyl

meta

1

CH 2 CO-1-(4-acety)piperazinyl

95

3-pyridyl

meta

1

CH 2 CONH(CH 2 ) 2 OH

96

3-pyridyl

meta

1

CH 2 CO-N-piperazinyl

97

3-pyridyl

meta

1

CH 2 CONH 2

98

3-pyridyl

para

1

CH 2 CONH 2

99

3-pyridyl

para

1

CH 2 CO-1-(4-acetyl)piperazinyl

100

3-pyridyl

para

1

CH 2 CO-N-piperazinyl

101

3-pyridyl

para

1

CH 2 CONH(CH 2 ) 2 OH

102

3-pyridyl

para

1

CH 2 CONH 2

103

2- furyl

ortho

1

CH 2 CON(CH 3 ) 2

104

2- furyl

ortho

1

CH 2 CONHCH 2 CN

105

2- furyl

ortho

1

CH 2 CONH(isopropyl)

106

2- furyl

ortho

1

CH 2 CONH 2

107

2- furyl

ortho

1

CH(OCH 3 )CONH 2

108

2- furyl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

109

2- furyl

ortho

1

CH 2 CO-1-(4-acetyl)piperazinyl

110

2- furyl

ortho

1

CH 2 COOH

111

2-furyl

meta

1

CH 2 CO-N-pyrrolidinyl

112

2-furyl

meta

1

CH 2 CON(CH 3 ) 2

113

2-furyl

meta

1

CH 2 CONH(isopropyl)

114

2-furyl

meta

1

CH 2 CONHCH 2 CN

115

2-furyl

meta

1

CH 2 CO-1-(4-acetyl)piperazinyl

116

2-furyl

meta

1

CH 2 CONH(CH 2 ) 2 0H

117

2-furyl

meta

1

CH 2 CO-N- (4-piperidinol)

118

2-furyl

meta

1

CH 2 CO-N-piperazinyl

119

2-furyl

meta

1

CH 2 CONH 2

120

2-furyl

meta

1

CH 2 CO-1-[4-(2-methoxyphenyl)]-

piperazinyl

121

2-furyl

meta

1

CH 2 CO-1-[4-(4-fluorophenyl)]-

piperazinyl

122

2-furyl

meta

1

CH 2 CO-1-(4-phenyl)piperazinyl

123

2-furyl

meta

1

CH 2 CONH 2

124

2-sele-

meta

1

CH 2 CO-1-(4-acetyl)piperazinyl

ninyl[[1]]

125

2-hydroxy-

meta

1

CH 2 CO-1-(4-acetyl)piperazinyl

phenyl

126

2-benzo-

meta

1

CH 2 CO-1-(4-acetyl)piperazinyl

furyl

127

2-benzo-

meta

1

CH 2 CONH(CH 2 ) 2 OH

furyl

128

2- furyl

para

1

CH 2 CONH 2

129

2- furyl

para

1

CH 2 CONH(isopropyl)

130

2- furyl

para

1

CH 2 CONHCH 2 CN

131

2- furyl

para

1

CH 2 CON(CH 3 ) 2

132

2- furyl

para

1

CH 2 CO-1-(4-acetyl)piperazinyl

133

2- furyl

para

1

CH 2 CONH(CH 2 ) 2 OH

134

2- furyl

para

1

CH 2 CO-N-piperazinyl

135

2-thienyl

ortho

1

CH 2 CO-N-pyrrolidinyl

136

2-(5-

ortho

1

CH 2 CO-N-pyrrolidinyl

bromo)-

thienyl

137

2-thienyl

ortho

1

CH 2 CON(CH 3 ) 2

138

2-(5-

ortho

1

CH 2 CON(CH 3 ) 2

bromo)-

thienyl

139

2-thienyl

ortho

1

CH 2 CONH 2

140

2-thienyl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

141

2-thienyl

ortho

1

CH 2 CO-N-piperazinyl

142

2-thienyl

ortho

1

CH 2 CO-1-(4-acetyl)piperazinyl

143

2-thienyl

ortho

1

CH 2 CONH(isopropyl)

144

2-thienyl

meta

1

CH 2 CO-N-pyrrolidinyl

145

2-thienyl

meta

1

CH 2 CON(CH 3 ) 2

146

2-thienyl

meta

1

CH 2 CONH 2

147

2-thienyl

meta

1

CH 2 CONH(CH 2 ) 2 OH

148

2-thienyl

meta

1

CH 2 CO-N-piperazinyl

149

2-thienyl

meta

1

CH 2 CO-1-(4-acetyl)piperazinyl

150

2-thienyl

para

1

CH 2 CO-N-pyrrolidinyl

151

2-(5-

para

1

CH 2 CO-N-pyrrolidinyl

bromo)-

thienyl

152

2-thienyl

para

1

CH 2 CON(CH 3 ) 2

153

2-(5-

para

1

CH 2 CON(CH 3 ) 2

bromo)-

thienyl

154

2-thienyl

para

1

CH 2 CONH 2

155

2-thienyl

para

1

CH 2 CONHCH 2 CN

156

2-thienyl

para

1

CH 2 CONH(isopropyl)

157

2-thienyl

para

1

CH 2 CO-1-(4-acetyl)piperazinyl

158

2-thienyl

para

1

CH 2 CONH(CH 2 ) 2 OH

159

2-thienyl

para

1

CH 2 CO-N-piperazinyl

436

2- furyl

ortho

2

CH 2 CO-1-(4-acetyl)piperazinyl

160

1,3-Dihydro-

ortho

1

CH 2 CO-N-pyrrolidinyl

isoindol-2-yl

161

1,3-Dihydro-

ortho

1

CH 2 CONMe 2

isoindol-2-yl

162

1,3-Dihydro-

meta

1

CH 2 CO-N-pyrrolidinyl

isoindol-2-yl

163

1,3-Dihydro-

meta

1

CH 2 CONMe 2

isoindol-2-yl

164

1,3-Dihydro-

meta

1

CH 2 CONHCHMe 2

isoindol-2-yl

165

1,3-Dihydro-

meta

1

CH 2 CONHCH 2CN

isoindol-2-yl

166

2-Benzofuryl

Ortho

1

CH 2 CO-1-piperazinyl

167

2-Benzofuryl

Ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

168

2-benzo-

Ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

[1,4]dioxine

169

2-benzo-

Ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

[1,4]dioxine

170

2-benzo-

Ortho

1

CH 2 CONHCH(CH 3 ) 2

[1,4]dioxine

171

Pyrrol-1-yl

meta

1

CH 2 CONH(CH 2 ) 2 OH

172

Pyrrol-1-yl

meta

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

173

Pyrrol-1-yl

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

174

Pyrrol-1-yl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

175

Pyrrol-1-yl

ortho

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

176

Pyrrol-1-yl

ortho

1

CH 2 CONH(CH 2 ) 2 O(CH 2 ) 2 OH

177

Pyrrol-1-yl

ortho

1

CH 2 CO-N-pyrrolidinyl

178

Pyrrol-1-yl

ortho

1

CH 2 CONMe 2

179

Pyrrol-1-yl

ortho

1

CH 2 CONHCHMe 2

180

Pyrrol-1-yl

ortho

1

CH 2 CO-1-(4-acetyl)-

piperazinyl

181

Pyrrol-1-yl

meta

1

CH 2 CONHCH 2 CN

182

Pyrrol-1-yl

meta

1

CH 2 CONHCHMe 2

183

Pyrrol-1-yl

meta

1

CH 2 CONMe 2

184

2-Benzofuryl

Ortho

1

CH 2 CON(CH 3 ) 2

185

2-Benzofuryl

Ortho

1

CH 2 CONHCH(CH 3 ) 2

186

Pyrrol-1-yl

ortho

1

CH 2 CONH 2

187

Pyrrol-1-yl

meta

1

CH 2 CONH 2

188

Pyrrol-1-yl

para

1

CH 2 CONH 2

190

2-benzo[1,4]-

ortho

1

CH 2 CONH 2

dioxine

191

2-Benzofuryl

Ortho

1

CH 2 CONH 2

192

1,3-Dihydro-

ortho

1

CH 2 CONH 2

isoindol-2-yl

193

1,3-Dihydro-

meta

1

CH 2 CONH 2

isoindol-2-yl

194

phenyl

ortho

1

CH 2 CON(CH 3 ) 2

195

phenyl

ortho

1

CH 2 CONH 2

196

phenyl

ortho

1

CH 2 CONHCH 3

197

phenyl

ortho

1

CH 2 CON(C 2 H 5 ) 2

198

phenyl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

199

phenyl

ortho

1

CH 2 CONHCH 2 -( 3 -

pyridyl)

200

phenyl

ortho

1

CH 2 CONH(cyclobutyl)

201

phenyl

ortho

1

CH 2 CONH-(cyclopentyl)

202

phenyl

ortho

1

CH 2 CO-N-pyrrolidinyl

203

phenyl

ortho

1

CH 2 CO-N-(2-carboxamide)-

pyrrolidinyl

205

phenyl

ortho

1

CH 2 CO-N-piperazinyl

206

phenyl

ortho

1

CH 2 CO-N-1-(4-t-

butylcarboxylate)-piperazinyl

207

phenyl

ortho

1

CH 2 CONHCH 2 CN

208

phenyl

ortho

1

CH 2 CO NHCH 2 CF 3

210

phenyl

ortho

1

CH 2 CONHCH(CH 3 ) 2

211

phenyl

para

1

CH 2 CO NH 2

212

phenyl

para

1

CH 2 CO-N-pyrrolidinyl

213

phenyl

para

1

CH 2 CO N(CH 3 ) 2

215

phenyl

Para

1

CH 2 CO-N-piperidinyl

216

phenyl

para

1

CH 2 CONH(CH 2 ) 2 -( 2 -

pyridyl)

217

phenyl

para

1

CH 2 CONHCH 2 -( 3 -

pyridyl)

218

phenyl

Para

1

CH 2 CONHCH(CH 3 ) 2

219

phenyl

Meta

1

CH 2 CONH 2

220

phenyl

Meta

1

CH 2 CON(CH 3 ) 2

221

phenyl

Meta

1

CH 2 CO-N-pyrrolidinyl

222

phenyl

Meta

1

CH 2 CONHCH(CH 3 ) 2

Ex. No.

Q

Ar

Y-R 1

Ar position

353

1

cyclohexen-1-yl

CH 2 CONH 2

ortho

354

1

cyclopenten-1-yl

CH 2 CONH 2

ortho

355

1

cyclohepten-1-yl

CH 2 CONH 2

ortho

356

1

Naphth-2-yl

CH 2 CONH 2

ortho

357

1

phenoxathiin-4-yl

CH 2 CONH 2

ortho

358

1

Quinolin-3-yl

CH 2 CONH 2

ortho

359

1

3,5-dimethyl-isoxazol-4-yl

CH 2 CONH 2

ortho

Ar

Ex. No.

q

Ar

position

Y-R 1

400

1

naphtha-2-yl

meta

CH 2 CONH 2

401

1

3,5-

meta

CH 2 CONH 2

dimethyl-isoxazol-

4-yl

Ar

Ex. No.

q

Ar

position

Y-R 1

430

1

(3,5-dimethyl)-

para

CH 2 CONH 2

isoxazol-4-yl

Ar

Ex. No.

Ar

Position

q

Y-R 1

431

2-benzothienyl

ortho

1

CH 3

432

3-thienyl

ortho

1

CH 3

433

2-furyl

para

1

CH 3

434

2-thienyl

para

1

CH 3

435

phenyl

ortho

1

CH 3

or a stereoisomeric form, mixture of stereoisomeric forms or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 or 3 wherein the compound is 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide, 2-(2-benzo[b]thiophen-5-yl-phenylmethanesulfinyl)-acetamide, 2-[2-(3-chloro-benzofuran-2-yl)-phenylmethanesulfinyl]-acetamide, or a stereoisomeric form, mixture of stereoisomeric forms or a pharmaceutically acceptable salt thereof or is a compound of selected from the following:

selected from

Ex. No.

Ar

437

4′-fluoro-3-benzothienyl

438

4′-fluoro-2-furyl

439

4′-fluoro-3-furyl

440

4′-fluoro-3-pyridyl

441

4′-fluoro-5-chloro-2-thienyl

442

5′-chloro-3-pyridyl

443

4′-fluoro-3-thienyl

444

4′-fluoro-5-chloro-2-benzothienyl

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 or 3 wherein the compound of Formula I has the following structure:

and is selected from the following:

Substitution on

Ex. No.

q

Biphenyl Moiety

Y-R 1

223

1

4′-COCH 3

CH 2 CONH 2

224

1

4′-F

CH 2 CONH 2

225

1

4′-CH3

CH 2 CONH 2

226

1

2′-CH3

CH 2 CONH 2

227

1

3′,5′-Difluoro

CH 2 CONH 2

228

1

3′,5′-Dimethyl

CH 2 CONH 2

229

1

3′-F

CH 2 CONH 2

230

1

2′-F

CH 2 CONH 2

231

1

2′-OEt

CH 2 CONH 2

232

1

3′-F,4′-Ph

CH 2 CONH 2

233

1

2′-OMe, 5′-F

CH 2 CONH 2

234

1

4′-OMe

CH 2 CONH 2

235

1

4′-OPh

CH 2 CONH 2

236

1

3′-CN

CH 2 CONH 2

237

1

3′CONH 2

CH 2 CONH 2

238

1

3′,5′-Dichloro

CH 2 CONH 2

239

1

3′-CF 3

CH 2 CONH 2

240

1

3′-SCH 3

CH 2 CONH 2

241

1

3′-SOMe

CH 2 CONH 2

242

1

3′-OCF 3

CH 2 CONH 2

243

1

3′-CONMe 2

CH 2 CONH 2

244

1

4′-OCF 3

CH 2 CONH 2

245

1

4 ′-CF 3

CH 2 CONH 2

246

1

4′-SCH 3

CH 2 CONH 2

247

1

4′-SOCH 3

CH 2 CONH 2

248

1

2′-Cl

CH 2 CONH 2

249

1

3′-Cl

CH 2 CONH 2

250

1

4′-Cl

CH 2 CONH 2

251

1

2′-OMe

CH 2 CONH 2

252

1

3′-OMe

CH 2 CONH 2

253

1

3′,4′-Dimethoxy

CH 2 CONH 2

254

1

3′,4′-Methylenedioxy

CH 2 CONH 2

255

1

3′,4 ′-Ethylenedioxy

CH 2 CONH 2

256

1

3′,4′-Propylenedioxy

CH 2 CONH 2

257

1

2′,6′-Dimethoxy

CH 2 CONH 2

258

1

2′,5′-Dimethoxy

CH 2 CONH 2

259

1

3′-NO 2

CH 2 CONH 2

260

1

2′-OH

CH 2 CONH 2

261

1

3′-OH

CH 2 CONH 2

262

1

4′-OH

CH 2 CONH 2

263

1

4′-CN

CH 2 CONH 2

264

1

3′-Me

CH 2 CONH 2

265

1

2′-OCF 3

CH 2 CONH 2

266

1

3′-Me, 4′-F

CH 2 CONH 2

267

1

2′-SMe

CH 2 CONH 2

268

1

3-Cl, 4′-F

CH 2 CONH 2

269

1

2′-OMe, 5′-Cl

CH 2 CONH 2

270

1

2′-SOMe

CH 2 CONH 2

271

1

4,5-(OMe) 2

CH 2 CONH 2

272

1

4′-Br

CH 2 CONH 2

273

1

2′-OMe, 4′-Cl

CH 2 CONH 2

274

1

2′-Me, 4′-Cl

CH 2 CONH 2

275

1

2′-Cl, 4′-Cl

CH 2 CONH 2

276

1

2′-CF 3

CH 2 CONH 2

277

1

2′-F, 4′-Br

CH 2 CONH 2

278

2

4′-Cl

CH 2 CONH 2

279

1

4′-CHMe 2

CH 2 CONH 2

280

1

4′-CMe 3

CH 2 CONH 2

281

2

4′-Me

CH 2 CONH 2

282

2

4′-F

CH 2 CONH 2

283

1

4′-Cl

(CH 2 ) 2 OH

284

1

3′-Br

CH 2 CONH 2

285

1

2′-Br

CH 2 CONH 2

286

1

4′-Cl

CH 2 CO-N-

pyrrolidinyl

287

1

4′-NMe 2

CH 2 CONH 2

288

1

4′-CH=CH 2

CH 2 CONH 2

289

1

4′-Cl

CH 2 CO-4-

acetylpiperazinyl

290

1

4′-SO 2 Me

CH 2 CONH 2

291

1

3′,4′-Cl 2

CH 2 CONH 2

292

1

4′-Et

CH 2 CONH 2

293

1

4′-CH 2 OMe

CH 2 CONH 2

294

1

4′-CO-N-(4-

CH 2 CONH 2

oxo)piperidinyl

295

1

4′-NHSO 2 Me

CH 2 CONH 2

296

1

4′-CONMe 2

CH 2 CONH 2

298

1

4′-Cyclohexyl

CH 2 CONH 2

299

1

3′,4′-F 2

CH 2 CONH 2

300

1

3′,4′,5′-OMe 3

CH 2 CONH 2

302

1

4′-Cl

(CH 2 ) 2 CONH 2

303

1

3′-NMe 2

CH 2 CONH 2

304

1

4′-CH 2 CHMe 2

CH 2 CONH 2

305

1

5-F, 4′-Cl

CH 2 CONH 2

306

1

3′-F, 4′-Cl

CH 2 CONH 2

307

1

5-F, 4′-Me

CH 2 CONH 2

308

1

5-F, 4′-F

CH 2 CONH 2

309

1

5-F, 4′-NMe 2

CH 2 CONH 2

310

1

3′-OMe, 4′-Cl

CH 2 CONH 2

311

1

3′,4′-F 2 , 5′-OMe

CH 2 CONH 2

312

1

3′-CF 3 , 4′-Cl

CH 2 CONH 2

313

1

4′-OCH 2 CHMe 2

CH 2 CONH 2

314

1

4′-COOMe

CH 2 CONH 2

315

1

4′-CH 2 OH

CH 2 CONH 2

316

1

4′-COOtBu

CH 2 CONH 2

317

1

3′,4′-Me 2

CH 2 CONH 2

318

1

3′-CF 3 , 4′-F

CH 2 CONH 2

319

1

3′-F, 4′-Me

CH 2 CONH 2

320

1

3′-Cl, 4′-Me

CH 2 CONH 2

321

1

3′-Me, 4′-Cl

CH 2 CONH 2

322

1

4,5-O-CH 2 -O, 4′-Cl

CH 2 CONH 2

323

1

4,5-OMe 2 , 4′-Cl

CH 2 CONH 2

324

1

4,5-O-CH 2 -O, 4′-F

CH 2 CONH 2

325

1

5-F, 3′, 4′-F 2

CH 2 CONH 2

326

1

4,5-O-CH 2 -O, 4′-Me

CH 2 CONH 2

327

1

4,5-O-CH 2 -O,

CH 2 CONH 2

3′, 4′-F 2

328

1

4,5-OMe 2 , 4′-F

CH 2 CONH 2

329

1

4,5-OMe 2 , 4′-Me

CH 2 CONH 2

330

1

4,5-OMe 2 , 3′, 4′-F 2

CH 2 CONH 2

331

1

3′-Me, 4′-OMe

CH 2 CONH 2

332

1

5-Cl, 4′-Cl

CH 2 CONH 2

333

1

3′,5′-Me 2 , 4′-Cl

CH 2 CONH 2

334

1

5-Cl, 4′-F

CH 2 CONH 2

335

1

3′-CF 3 , 4′-Me

CH 2 CONH 2

336

1

3′-NO 2 , 4′-Cl

CH 2 CONH 2

337

1

4-F, 4′-Cl

CH 2 CONH 2

338

1

5-Cl, 3′,4′-F 2

CH 2 CONH 2

339

2

5-F, 4′-Cl

CH 2 CONH 2

340

1

4′-F

(CH 2 ) 2 CONH 2

341

1

4-F, 4′-F

CH 2 CONH 2

342

1

4-F, 4′-Me

CH 2 CONH 2

343

1

4-F, 3′, 4′-F 2

CH 2 CONH 2

344

2

3′, 4′-F 2

CH 2 CONH 2

345

1

5-Cl, 4′-Me

CH 2 CONH 2

346

1

4-OMe, 4′-Cl

CH 2 CONH 2

347

1

6-Me, 4′-Cl

CH 2 CONH 2

348

1

6-Me, 3′,4′-Cl 2

CH 2 CONH 2

349

1

4-OMe, 3′,4′-Cl 2

CH 2 CONH 2

350

1

4-Cl, 4′-Cl

CH 2 CONH 2

351

1

4-F, 3′,4′-Cl 2

CH 2 CONH 2

352

1

6-Me, 3′-F, 4′-Cl

CH 2 CONH 2

402

1

3-F

CH 2 CONH 2

403

1

2′-Cl

CH 2 CONH 2

404

1

3′-Cl

CH 2 CONH 2

405

1

4′-OMe

CH 2 CONH 2

406

1

3′,4′-Methylenedioxy

CH 2 CONH 2

407

1

2′,6′-(OMe) 2

CH 2 CONH 2

408

1

4′-Cl

CH 2 CONH 2

409

1

3′,4′-(OMe) 2

CH 2 CONH 2

410

1

3′-OMe

CH 2 CONH 2

411

1

4′-CN

CH 2 CONH 2

412

1

2′,5′-(OMe) 2

CH 2 CONH 2

413

1

3′-NO 2

CH 2 CONH 2

414

1

3′-Me

CH 2 CONH 2

415

1

2′-OMe

CH 2 CONH 2

416

1

2′-Me, 4′-Cl

CH 2 CONH 2

417

1

2′-OMe, 4′-Cl

CH 2 CONH 2

418

1

2′, 4′-Cl 2

CH 2 CONH 2

419

2

3′,4′-(OMe) 2

CH 2 CONH 2

420

1

3′,4′-Cl 2

CH 2 CONH 2

421

1

3-F, 4′-Cl

CH 2 CONH 2

422

1

3-F, 4′-Me

CH 2 CONH 2

423

1

4′-Br

CH 2 CONH 2

424

1

3′-Cl, 4′-OMe

CH 2 CONH 2

425

1

3′,4′,5′-(OMe) 3

CH 2 CONH 2

426

1

3′,4′-F 2

CH 2 CONH 2

427

1

3-F, 4′-F

CH 2 CONH 2

428

2

3-F, 4′-F

CH 2 CONH 2

429

1

3-F, 4′-Cl

CH 2 CONH 2

402

1

3-F

CH 2 CONH 2

403

1

2′-Cl

CH 2 CONH 2

404

1

3′-Cl

CH 2 CONH 2

405

1

4′-OMe

CH 2 CONH 2

406

1

3′,4′-Methylenedioxy

CH 2 CONH 2

407

1

2′,6′-(OMe) 2

CH 2 CONH 2

408

1

4′-Cl

CH 2 CONH 2

409

1

3′,4′-(OMe) 2

CH 2 CONH 2

410

1

3′-OMe

CH 2 CONH 2

411

1

4′-CN

CH 2 CONH 2

412

1

2′,5′-(OMe) 2

CH 2 CONH 2

413

1

3′-NO 2

CH 2 CONH 2

414

1

3′-Me

CH 2 CONH 2

415

1

2′-OMe

CH 2 CONH 2

416

1

2′-Me, 4′-Cl

CH 2 CONH 2

417

1

2′-OMe, 4′-Cl

CH 2 CONH 2

418

1

2′, 4′-Cl 2

CH 2 CONH 2

419

2

3′,4′-(OMe) 2

CH 2 CONH 2

420

1

3′,4′-Cl 2

CH 2 CONH 2

421

1

3-F, 4′-Cl

CH 2 CONH 2

422

1

3-F, 4′-Me

CH 2 CONH 2

423

1

4′-Br

CH 2 CONH 2

424

1

3′-Cl, 4′-OMe

CH 2 CONH 2

425

1

3′,4′,5′-(OMe) 3

CH 2 CONH 2

426

1

3′,4′-F 2

CH 2 CONH 2

427

1

3-F, 4′-F

CH 2 CONH 2

428

2

3-F, 4′-F

CH 2 CONH 2

429

1

3-F, 4′-Cl

CH 2 CONH 2

or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Jan 24, 2013
From: CEPHALON FRANCE
To: TEVA SANTE
Reel/Frame 029692/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2010
From: BACON, EDWARD R.; CHATTERJEE, SANKAR; DUNN, DEREK; HOSTETLER, GREG; IQBAL, MOHAMED; GOURDEL, MARIE-EDITH; LESUR, BRIGITTE; LOUVET, PHILIPPE; RIGUET, ERIC; SCHWEIZER, DOMINIQUE; YUE, CHRISTOPHE
To: CEPHALON, INC.; CEPHALON FRANCE
Reel/Frame 024788/0328 →